Cover Image
市場調查報告書

鈉·氯化物依賴性甘氨酸運輸體 1 :開發中產品分析

Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 364857
出版日期 內容資訊 英文 32 Pages
訂單完成後即時交付
價格
Back to Top
鈉·氯化物依賴性甘氨酸運輸體 1 :開發中產品分析 Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Pipeline Review, H2 2016
出版日期: 2016年11月09日 內容資訊: 英文 32 Pages
簡介

本報告提供以鈉·氯化物依賴性甘氨酸運輸體 1為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

鈉·氯化物依賴性甘氨酸運輸體 1 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 初期階段的產品

企業開發中的產品

大學/研究機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各分子類型

治療藥的開發企業

  • Karuna Pharmaceuticals Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0653TDB

Summary

Global Markets Direct's, 'Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Pipeline Review, H2 2016', provides in depth analysis on Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted pipeline therapeutics.

The report provides comprehensive information on the Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9)
  • The report reviews Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents 2
  • List of Tables 3
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) Overview 6
  • Therapeutics Development 7
  • Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Products under Development by Stage of Development 7
  • Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Products under Development by Therapy Area 8
  • Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Products under Development by Indication 9
  • Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Pipeline Products Glance 10
  • Late Stage Products 10
  • Early Stage Products 11
  • Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Products under Development by Companies 12
  • Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Products under Development by Universities/Institutes 14
  • Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Therapeutics Assessment 16
  • Assessment by Monotherapy/Combination Products 16
  • Assessment by Mechanism of Action 17
  • Assessment by Route of Administration 18
  • Assessment by Molecule Type 19
  • Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Companies Involved in Therapeutics Development 20
  • Pfizer Inc. 20
  • Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Drug Profiles 21
  • CSTI-200 - Drug Profile 21
  • Product Description 21
  • Mechanism Of Action 21
  • R&D Progress 21
  • DNS-006 - Drug Profile 22
  • Product Description 22
  • Mechanism Of Action 22
  • R&D Progress 22
  • PF-03463275 - Drug Profile 23
  • Product Description 23
  • Mechanism Of Action 23
  • R&D Progress 23
  • PGW-5 - Drug Profile 25
  • Product Description 25
  • Mechanism Of Action 25
  • R&D Progress 25
  • Small Molecule to Inhibit GlyT1 for Schizophrenia and Parkinson's Disease - Drug Profile 26
  • Product Description 26
  • Mechanism Of Action 26
  • R&D Progress 26
  • VU-0410120 - Drug Profile 27
  • Product Description 27
  • Mechanism Of Action 27
  • R&D Progress 27
  • Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Dormant Projects 28
  • Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Discontinued Products 30
  • Appendix 31
  • Methodology 31
  • Coverage 31
  • Secondary Research 31
  • Primary Research 31
  • Expert Panel Validation 31
  • Contact Us 31
  • Disclaimer 32

List of Tables

  • Number of Products under Development for, H2 2016 7
  • Number of Products under Development by Therapy Area, H2 2016 8
  • Number of Products under Development by Indication, H2 2016 9
  • Comparative Analysis by Late Stage Development, H2 2016 10
  • Comparative Analysis by Early Stage Products, H2 2016 11
  • Number of Products under Development by Companies, H2 2016 12
  • Products under Development by Companies, H2 2016 13
  • Number of Products under Investigation by Universities/Institutes, H2 2016 14
  • Products under Investigation by Universities/Institutes, H2 2016 15
  • Assessment by Monotherapy/Combination Products, H2 2016 16
  • Number of Products by Stage and Mechanism of Action, H2 2016 17
  • Number of Products by Stage and Route of Administration, H2 2016 18
  • Number of Products by Stage and Molecule Type, H2 2016 19
  • Pipeline by Pfizer Inc., H2 2016 20
  • Dormant Projects, H2 2016 28
  • Dormant Projects (Contd..1), H2 2016 29
  • Discontinued Products, H2 2016 30

List of Figures

  • Number of Products under Development for, H2 2016 7
  • Number of Products under Development by Top 10 Indication, H2 2016 9
  • Assessment by Monotherapy/Combination Products, H2 2016 16
  • Number of Products by Stage and Mechanism of Actions, H2 2016 17
  • Number of Products by Stage and Molecule Type, H2 2016 19
Back to Top